Autologous tumor-infiltrating lymphocytes expanded ex vivo are infused after lymphodepleting chemotherapy; they recognize tumor antigens via native TCRs and mediate antigen-specific cytotoxicity, persisting and expanding in vivo to repopulate with highly tumor-reactive T cells.